Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?

Radiology

Volumn 248, Issue 2, 2008, Pages 323-325

  Goldberg, S Nahum ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER INHIBITION; CANCER MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; HIGH INTENSITY FOCUSED ULTRASOUND; INTERVENTIONAL RADIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; ANIMAL; MULTIMODALITY CANCER THERAPY; NOTE; ULTRASOUND THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; MICE; PYRAZINES; ULTRASONIC THERAPY;

EID: 49049085299     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2482080719     Document Type: Short Survey

References (15)

1. Poff JA, Allen C, Traughber B. Pulsed high-intensity focused US enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology 2008;248(2):485-491.
2. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 2003;4(5):337-341.
3. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46(1-3):149-168.
4. Livraghi T. Role of percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Dig Dis 2001;19(4):292-300.
5. Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 2002;54(2):159-180.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37(2):429-442.
7. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25(8):978-986.
8. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004;240(6):939-947.
9. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003;19(3):267-294.
10. Zaffaroni N, Fiorentini G, De Giorgi U. Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol 2001;27(4):340-342.
11. Monsky WL, Kruskal JB, Lukyanov AN, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 2002;224(3):823-829.
12. Ahmed M, Goldberg SN. Combination radio-frequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 2004;20(7):781-802.
13. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007;13(9):2722-2727.
14. Orr RM. Technology evaluation: electroporation therapy, Genetronics Inc. Curr Opin Mol Ther 2000;2(2):205-210.
15. Rieke V, Butts, Pauly K. MR thermometry. J Magn Reson Imaging 2008;27(2):376-390.